SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Shukra Pharmaceuticals Ltd

BSE: 524632 NSE: ISIN: INE551C01044
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Shukra Pharmaceuticals Ltd belong to?
Shukra Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Shukra Pharmaceuticals Ltd a good quality company?
Shukra Pharmaceuticals Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Shukra Pharmaceuticals Ltd undervalued or overvalued?
Shukra Pharmaceuticals Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Shukra Pharmaceuticals Ltd a good buy now?
Shukra Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd revenue growth is -56.3% for FY-2025 , which is below its 5 year CAGR of 22.4% , indicating slower growth.
Q.2 Gross Profit margin of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 50.2% for FY-2025 , which is above its 5 year median of 15.8% , indicating increasing margins.
Q.3 Operating Profit Margin of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 39.06% for FY-2025 , which is above its 5 year median of 14.09% indicating increasing margins.
Q.4 Net Profit Margin of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Net Profit Margin is 29.38% for FY-2025 , is above with its 5 year median of 7.49%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 50.2 15.8
Operating Profit Margin 39.06 14.09
Net Profit Margin 29.38 7.49
Q.5 Return on Asset of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Return on Asset is 11.63%, which is above its 5 year historical median of 8.01%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Return on equity is 15.9% for FY-2025 , which is in line with its historical median of 15.9%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Return on capital employed is 21.8% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Cash conversion cycle is 111 days, above its historical median of 54 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.4 0.58
ROE 15.9 15.9
ROCE 21.8 18.85
Cash Conversion Cycle 111 days 54 days
Q.9 Debt to Equity ratio of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Debt-to-Equity ratio is 0.07 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd Debt to cash flow from operations is 0.53 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Shukra Pharmaceuticals Ltd?
Promoters hold 50.96% of the Shukra Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Shukra Pharmaceuticals Ltd vs industry peers?
Shukra Pharmaceuticals Ltd revenue CAGR is 22.43% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 32.6 137.1
Gross Profit 16.6 15.1
Operating Profit 13 16
Net Profit 10 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.4 0.8
ROE 15.9 8.91
ROCE 21.8 11.59
Cash Conversion Cycle (days) 111.1 76

Valuation & price assessment

Q.1 Stock return of Shukra Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 59.4% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 59.4% 158.9% 185.5% 84.9%
Q.3 Valuation ratios of Shukra Pharmaceuticals Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 53.08 309.58 40.28
Price to Book 17.96 0.66 2.77
Price to Sales 24.31 0.71 2.65
EV to EBITDA 38.02 9.76 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×